Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by FORA Capital LLC

Key Points

• FORA Capital LLC increased its stake in Regeneron Pharmaceuticals by 113.4%, holding a position worth approximately $3.46 million after acquiring additional shares in the first quarter.
• Regeneron Pharmaceuticals reported earnings of $12.89 per share, significantly surpassing analysts' estimates of $8.43, with a total revenue of $3.675 billion for the quarter.
• The company declared a quarterly dividend of $0.88 per share, reflecting a modest annualized dividend yield of 0.6% and a payout ratio of 8.87%.

FORA Capital LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 113.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,447 shares of the biopharmaceutical company's stock after buying an additional 2,894 shares during the quarter. FORA Capital LLC's holdings in Regeneron Pharmaceuticals were worth $3,455,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its stake in shares of Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after acquiring an additional 814,713 shares during the period. Nuveen LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $343,764,000. Pacer Advisors Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 2,296.9% in the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock valued at $258,366,000 after buying an additional 390,374 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Regeneron Pharmaceuticals by 171.0% in the first quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock valued at $305,311,000 after buying an additional 303,785 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Regeneron Pharmaceuticals by 30.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock worth $699,554,000 after acquiring an additional 226,952 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 1.3%

Shares of NASDAQ REGN traded down $7.35 during midday trading on Thursday, hitting $579.61. The stock had a trading volume of 616,549 shares, compared to its average volume of 1,082,231. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,210.97. The company has a fifty day moving average price of $555.84 and a 200 day moving average price of $588.67. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $61.43 billion, a price-to-earnings ratio of 14.61, a PEG ratio of 1.96 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the firm earned $11.56 earnings per share. The company's revenue for the quarter was up 3.6% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Argus downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Jefferies Financial Group lifted their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research report on Wednesday. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Finally, Royal Bank Of Canada boosted their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a report on Monday, August 4th. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.